AMC SLE antibodies.

Generation of Anti-Cytokine Antibodies from B Cells of Patients with Systemic Lupus Erythematosus.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON20754

Enrollment

Registered

2011-05-23

Start date

2011-05-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus, SLE

Interventions

No intervention, observational study with invasive measurements.

Eligibility

Inclusion criteria

Inclusion criteria: Male and female patients with a diagnosis of SLE and whose serum contains autoantibodies against type I IFNs.

Exclusion criteria

Exclusion criteria: 1. Use of or history of use of B cell-directed therapies; 2. Pregnancy.

Design outcomes

Primary

Measure	Time frame
The primary goal is to investigate the possibility of generating fully human monoclonal antibodies against type I interferons (IFNs) from B cells of SLE patients.	—

Contacts

Public ContactP.P. Tak

Academic Medical Center (AMC), Department of Clinical Immunology and Rheumatology, P.O. Box 22660

p.p.tak@amc.nl+31 (0)20 5662171

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)